title: Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders.
abstract: Soluble HLA-class I and CD8 molecules were determined by sandwich ELISA in patients with viral-induced hepatic disorders. As a whole, the patients with hepatic disorders (acute hepatitis: AH; chronic hepatitis: CH; liver cirrhosis: LC; hepatocellular carcinoma: HCC) showed higher sHLA-class I and sCD8 levels than normal controls (P < 0.001). AH patients had the highest sHLA-class I levels (mean, 3513 +/- 2112 ng/ml), followed by CH (2896 +/- 1290 ng/ml), LC (2293 +/- 1266 ng/ml), and HCC (2221 +/- 1212 ng/ml) sCD8 levels wer highest in AH, followed by HCC, LC, and CH, in that order. Among histologically defined C virus-positive patients, sHLA-I levels were higher in those with chronic active hepatitis (CAH) 2A (3802 +/- 1124 ng/ml) than in those with chronic persistent hepatitis (CPH; 2200 +/- 711 ng/ml; P < 0.01), the levels then decreased as the disease progressed (CAH2B, 3564 +/- 1783 ng/ml, LC, 2376 +/- 1265 ng/ml). In contrast, sCD8 values showed little difference among the disorders. sHLA-class I levels showed a positive correlation with sCD8 values both in whole patients and in patients with AH (P < 0.01), but no correlation was shown, in any patients, with biochemical parameters such as GPT and GOT. These findings, taken together, suggest that hepatic destruction is not the only cause of sHLA-class I production, but that sHLA-class I levels, together with sCD8 levels, may reflect immunological activity in hepatic disorders.
authors.affiliation: Department of Transplantation Immunology, Tokai University School of Medicine, Kanagawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hagihara
authors.forename: T
authors.initials: T
authors.lastname: Shimura
authors.forename: K
authors.initials: K
authors.lastname: Takebe
authors.forename: B
authors.initials: B
authors.lastname: Munkhbat
authors.forename: K
authors.initials: K
authors.lastname: Hosoi
authors.forename: T
authors.initials: T
authors.lastname: Kagawa
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Matsuzaki
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Tsuji
mesh_terms: D016827:CD8 Antigens / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006526:Hepatitis C / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000097:blood*; D006801:Humans; D008103:Liver Cirrhosis / Q000276:immunology; D008107:Liver Diseases / Q000276:immunology* / Q000821:virology*; D008113:Liver Neoplasms / Q000276:immunology
chemical_list: D016827:CD8 Antigens; D015395:Histocompatibility Antigens Class I